Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
荷蘭最大的一期DMT研究，Entheon和Cybin的合作
Cybin Inc. (NEO:CYBN) (NYSE:CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine ("DMT") study from Entheon Biomedical Corp. (CSE:ENBI) (OTCQB:ENTBF) to accelerate the clinical development path for CYB004, Cybin's proprietary deuterated DMT molecule for the potential treatment of anxiety disorders.
亞洲網加利福尼亞州聖何塞10月23日電Cybin Inc.(紐約證券交易所代碼：CEBE)宣佈，它已通過其全資子公司Cybin IRL Limited達成協議，從Entheon Biomedical Corp.(CSE：ENBI)(OTCQB：ENTBF)手中收購一項N，N-二甲基色胺(DMT)第一階段研究，以加快Cybin的專有DMT分子CyB004的臨牀開發道路。
Both companies confirmed that they will be working together in the phase 1 study addressed at testing the effects of DMT in healthy smokers. Originally named the EBRX-101 study, Cybin's acquisition changed it to CYB004-E, as it will use the novel...
兩家公司證實，他們將在第一階段研究旨在測試DMT對健康吸煙者的影響。最初命名為EB...
登入免費觀看全文
登入/註冊